Why the study?
Older adults with heart failure have high event rates but are complex and underrepresented in landmark trials, leaving unclear the net benefit of guideline-directed medical therapies and optimal deprescribing strategies.
Design
Editorial
Authors
Loading...
Supports deprescribing trials in frail older HF patients; leaves open confirmation before changing practice.
Managing heart failure in complex, frail older adults requires a tailored, patient-centered approach to balance the benefits of guideline-directed medical therapy against the risks of polypharmacy and adverse drug reactions.
Linden et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: